Johns Hopkins Sjögren’s Center

Home / POETYK SjS-1 Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjogrens Syndrome and Extension

POETYK SjS-1 Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjogrens Syndrome and Extension

Overview
The POETYK study and its extension evaluated the efficacy and safety of the pharmaceutical Deucravacitinib in patients with active Sjögren’s disease.

Key Facts

  • Status: Active
  • Dates: January 2024 – Present
  • Principal Investigator: Thomas Grader-Beck, MD
  • Sponsor: Bristol-Myers Squibb
  • Location: our branch of the study was conducted at the Johns Hopkins Jerome L. Greene Sjögren’s Center in Baltimore, MD

Study Design
The study involved patients over 18 years of age who were diagnosed with Sjogren’s, had particular clinical findings such as a certain level of salivary flow, and were experiencing higher levels of disease activity.

Results
To view results and ongoing discoveries related to this trial, see the Clinical Trials Page.

Impact
This research has provided valuable knowledge about Sjögren’s disease that is likely to facilitate the development of better treatments.

Use of this Site

All information contained within the Johns Hopkins Jerome L. Green Sjogren’s Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.